1. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagons-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations;Nauck;J. Clin. Endocrinol. Metab.,1993
2. Reduced postprandial concentrations of intact biologically active glucagons like peptide-1 in Type 2 diabetic patients;Vilsboll;Diabetes,2001
3. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagons like peptide-1-(7-36) amide in type II (noninsulin-dependent) diabetic patients;Willms;J. Clin. Endocrinol. Metab.,1996
4. Glucagonostatic and insulinotropic action of glucagon-like peptide-1 (7-36) amide;Komatsu;Diabetes,1989
5. Antidiabetogenic effect of glucagons like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus;Gutniak;New Engl. J. Med.,1992